Tracking a new eye treatment for the tiniest patients

NCT ID NCT06315556

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study aims to count how many premature babies in the UK with a serious eye condition (retinopathy of prematurity) are being treated with Eylea injections using a special pediatric dosing device. Researchers will use existing hospital records to gather this information, with no extra visits or tests for the babies. The goal is to see if enough babies are receiving this treatment to justify a future, larger study on its long-term safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRETERM INFANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Many locations

    RECRUITING

    Multiple Locations, United Kingdom

Conditions

Explore the condition pages connected to this study.